-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TAA-Specific CTLs in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TAA-Specific CTLs in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TAA-Specific CTLs in Breast Cancer Drug Details: Tumor Associated Antigen (TAA)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TAA-Specific CTLs in Multiple Myeloma (Kahler Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TAA-Specific CTLs in Multiple Myeloma (Kahler Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TAA-Specific CTLs in Multiple Myeloma (Kahler Disease) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anti-CD19-CAR in B-Cell Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anti-CD19-CAR in B-Cell Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anti-CD19-CAR in B-Cell Leukemia Drug Details: Gene therapy is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gene Therapy For Relapsed And Refractory Multiple Myeloma in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy For Relapsed And Refractory Multiple Myeloma in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gene Therapy For...
-
Product Insights
NewHodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Drugs In Development, 2024
Empower your strategies with our Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Drugs In Development, 2024 report and make more profitable business decisions. Hodgkin lymphoma is a cancer that starts in white blood cells called lymphocytes. Symptoms include painless swelling of the lymph nodes in the neck, armpits, or groin, fever and chills, night sweats, weight loss, loss of appetite, and itchy skin. Hodgkin lymphoma is most common among people ages 15 to 35 and 50 to 70. Past infections with the...
-
Product Insights
NewDuctal Carcinoma – Drugs In Development, 2024
Empower your strategies with our Ductal Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Ductal Carcinoma is early stage of breast cancer where the ductal cells of the breast tissue tend to multiply or grow uncontrollably without any evidence of metastatic. If not treated in initial stages, this could be invasive. Ductal carcinoma is represented in 4 different stages, pre invasive, non-invasive, ductal intraepithelial neoplasia, intra ductal cancer. In invasive form spread of cancer cells into...
-
Product Insights
NewPlasma Cell Neoplasm – Drugs In Development, 2024
Empower your strategies with our Plasma Cell Neoplasm – Drugs In Development, 2024 report and make more profitable business decisions. Plasma Cell Neoplasm or plasma cell cancer is a group of diseases involving B-cells. These tumors are found in soft tissues that can be malignant or benign. Multiple Myeloma, lymphoplasmacytic lymphoma, plasmacytoma are the types of plasma cell cancers. Of all three multiple Myeloma is the most common and aggressive form. Age, chronic infection, exposure to radiation, hereditary factors, are some...
-
Product Insights
NewMammary Ductal Carcinoma – Drugs In Development, 2024
Empower your strategies with our Mammary Ductal Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Ductal carcinoma is a type of breast cancer that occurs in the milk ducts and moves into nearby tissues. There are two types of ductal carcinoma, invasive ductal carcinoma (IDC) and ductal carcinoma in situ (DCIS). If the abnormal cancer cells are seen inside the milk ducts, then it is DCIS. DCIS is also known as intraductal carcinoma or non-invasive ductal...
-
Product Insights
NewDuctal Carcinoma In Situ – Drugs In Development, 2024
Empower your strategies with our Ductal Carcinoma In Situ – Drugs In Development, 2024 report and make more profitable business decisions. Ductal carcinoma in situ (DCIS), also referred to as intraductal carcinoma, is a non-invasive breast cancer characterized by a proliferation of abnormal epithelial cells confined within the basement membrane. Disruption of the basement membrane layer would change the diagnosis from DCIS to invasive breast cancer. DCIS is considered to be a precursor for invasive breast cancer. The Ductal Carcinoma In...